Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3062573 | 0.90 | SMN1; SMN2 (0.77) | SMN1; SMN2MAPK1L3MBTL1TSHRPOLB | |
| SCHEMBL3079261 | 0.88 | SMN1; SMN2 (0.74) | SMN1; SMN2MAPK1L3MBTL1TSHRPOLB | |
| SCHEMBL17911621 | 0.85 | LMNA (0.52) | SMN1; SMN2MAPK1L3MBTL1TSHRPOLB | |
| SCHEMBL31474821 | 0.83 | NPC1 (0.59) | SMN1; SMN2MAPK1L3MBTL1TSHRPOLB | |
| SCHEMBL30674616 | 0.81 | L3MBTL1 (0.58) | SMN1; SMN2MAPK1L3MBTL1POLBLMNA | |
| SCHEMBL3528579 | 0.81 | L3MBTL1 (0.58) | SMN1; SMN2MAPK1L3MBTL1POLBLMNA | |
| SCHEMBL3069851 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2MAPK1L3MBTL1TSHRPOLB | |
| SCHEMBL10661800 | 0.79 | SMN1; SMN2 (0.73) | SMN1; SMN2MAPK1L3MBTL1TSHRPOLB | |
| SCHEMBL11568120 | 0.79 | SMN1; SMN2 (0.80) | SMN1; SMN2MAPK1L3MBTL1TSHRPOLB | |
| SCHEMBL7332384 | 0.79 | SMN1; SMN2 (0.73) | SMN1; SMN2MAPK1L3MBTL1TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197813-A1 | Heterocyclic Compounds as Sweetener Enhancers | REDPOINT BIO CORPORATION (US) | 2010-08-05 | — | — | US | disclosed |
| EP-0822814-A4 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1998-12-09 | — | — | EP | disclosed |
| EP-0822814-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1998-02-11 | — | — | EP | disclosed |
| US-5668148-A | BENIGN PROSTATIC HYPERTROPHY | MERCK & CO., INC. (US) | 1997-09-16 | — | — | US | disclosed |
| US-5605896-A | Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1997-02-25 | — | — | US | disclosed |
| WO-1996032938-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1996-10-24 | — | — | WO | disclosed |
| US-5474994-A | Treating hypertension, urethral and lower urinary tract contractions | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1995-12-12 | — | — | US | disclosed |
| EP-0445026-B1 | Aminomethylpiperidine derivatives, their process for preparation and the pharmaceutical compositions containing them | ADIR (FR) | 1994-01-26 | — | — | EP | disclosed |
| WO-1993017007-A1 | HETEROBICYCLIC COMPOUNDS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A. (IT) | 1993-09-02 | — | — | WO | disclosed |
| EP-0558245-A1 | Heterobicyclic compounds as antagogists of alpha-1 adrenergic and SHT1A receptors | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1993-09-01 | — | — | EP | disclosed |
| US-5229399-A | Analgesics | ADIR ET COMPAGNIE (FR) | 1993-07-20 | — | — | US | disclosed |
| US-5229398-A | Analgesics | ADIR ET COMPAGNIE (FR) | 1993-07-20 | — | — | US | disclosed |
| US-5192775-A | Analgesics | ADIR ET COMPAGNIE (FR) | 1993-03-09 | — | — | US | disclosed |
| EP-0445026-A1 | Aminomethylpiperidine derivatives, their process for preparation and the pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1991-09-04 | — | — | EP | disclosed |
| US-4027028-A | HYPOTENSIVE AGENTS | SCIENCE UNION ET CIE (FR) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197813-A1 | Heterocyclic Compounds as Sweetener Enhancers | TAS2R1, TAS1R1, TAS2R40 | SMN1; SMN2 1710/4885MAPK1 1957/4885L3MBTL1 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.